Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Cahill

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
Neuro-Oncology|November 4, 2024
Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect groupPhilipp Karschnia, Jacob S Young, Gilbert C Youssef, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2019
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial TumorsKensuke Tateishi, Taishi Nakamura, Tareq A Juratli, et al.
Nature Medicine|January 16, 2026
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trialPriscilla K Brastianos, Katharine Dooley, Susan Geyer, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Nature Medicine|June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial resultsPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Nature Communications|October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosisPriscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.
Neuro-Oncology|February 8, 2017
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomasGanesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, et al.
Nature Medicine|June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Cancer Cell|September 3, 2013
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastomaKrishna P L Bhat, Veerakumar Balasubramaniyan, Brian Vaillant, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
Neuro-Oncology|November 4, 2024
Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect groupPhilipp Karschnia, Jacob S Young, Gilbert C Youssef, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2019
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial TumorsKensuke Tateishi, Taishi Nakamura, Tareq A Juratli, et al.
Nature Medicine|January 16, 2026
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trialPriscilla K Brastianos, Katharine Dooley, Susan Geyer, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Nature Medicine|June 2, 2023
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial resultsPriscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, et al.
Nature Communications|October 13, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosisPriscilla K Brastianos, Matthew R Strickland, Eudocia Quant Lee, et al.
Neuro-Oncology|February 8, 2017
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomasGanesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, et al.
Nature Medicine|June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Cancer Cell|September 3, 2013
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastomaKrishna P L Bhat, Veerakumar Balasubramaniyan, Brian Vaillant, et al.
Pageof 20